Human cytomegalovirus (CMV) infections and relapse of disease remain major problems after allogeneic stem cell transplantation (allo-SCT), in particular in combination with CMV-negative donors or cordblood transplantations. Recent data suggest a paradoxical association between CMV reactivation after allo-SCT and reduced leukemic relapse. Given the potential of Vd2-negative gdT cells to recognize CMV-infected cells and tumor cells, the molecular biology of distinct gdT-cell subsets expanding during CMV reactivation after allo-SCT was investigated. Vd2 neg gdT-cell expansions after CMV reactivation were observed not only with conventional but also cordblood donors. Expanded gdT cells were capable of recognizing both CMV-infected cells and primary leukemic blasts. CMV and leukemia reactivity were restricted to the same clonal population, whereas other Vd2 neg T cells interact with dendritic cells (DCs). Cloned Vd1 T-cell receptors (TCRs) mediated leukemia reactivity and DC interactions, but surprisingly not CMV reactivity. Interestingly, CD8aa expression appeared to be a signature of gdT cells after CMV exposure. However, functionally, CD8aa was primarily important in combination with selected leukemia-reactive Vd1 TCRs, demonstrating for the first time a co-stimulatory role of CD8aa for distinct gdTCRs. Based on these observations, we advocate the exploration of adoptive transfer of unmodified Vd2 neg gdT cells after allo-SCT to tackle CMV reactivation and residual leukemic blasts, as well as application of leukemia-reactive Vd1 TCR-engineered T cells as alternative therapeutic tools.
INTRODUCTION
Human cytomegalovirus (CMV) is a widely prevalent herpesvirus that, after primary infection, persists lifelong in the human host. Although infections are asymptomatic in most immunocompetent individuals, reactivation of the virus in immunocompromised patients after allogeneic stem cell transplantation (allo-SCT) can lead to life-threatening complications including colitis and pneumonia. 1 Moreover, CMV infection is associated with increased risk of acute graft-versus-host disease 2, 3 and predisposes to secondary infections due to CMV-induced immunesuppression. 4 Paradoxically, recent evidence shows that CMV reactivation after allo-SCT reduces the risk of leukemic relapse, 5, 6 suggesting an unexpected favorable association between CMV infection and clearance of tumor.
Multiple cell populations have been reported to be involved in clearance of CMV infection. A vast body of information has been gathered for CMV-specific abT cells and natural killer (NK) cells. 7 For NK cells, it has been hypothesized that they may crossrecognize CMV-infected cells and cancer cells by responding to CMV-infected residual acute myeloid leukemia (AML) blasts, 6 which may contain considerable CMV copy numbers. An alternative population that might also contribute to a better control of leukemia after CMV reactivation is represented by gdT cells. In recent years, numerous studies have established the importance of gdT cells, a minor T-cell population in peripheral blood but prominently present at sites of CMV replication such as epithelial tissues, in both antiviral immunity and tumor surveillance. 8 Contrary to abT cells, activation of gdT cells does not rely on antigen presentation by major histocompatibility complex (MHC) but is instead mediated by pathogen-derived antigens or self molecules that are upregulated on infected, transformed or otherwise stressed cells. In adult peripheral blood, the major gdT-cell subset expresses T-cell receptors (TCRs) composed of Vd2 and Vg9 gene segments (therefore, also referred to as Vd2 pos gdT cells) and is activated by small, nonpeptidic phosphoantigens of pathogen or self-origin. 9, 10 In contrast, gdT cells that reside in epithelial tissues express TCRs composed of mainly Vd1 or Vd3 chains paired with diverse Vg chains, and a proportion of these gdT cells (collectively called Vd2 neg gdT cells) expresses CD8aa. 11, 12 The involvement of gdT cells in the immune response against CMV has been established by studies in transplant patients as well as healthy individuals, showing that CMV infection associates with marked in vivo expansions of specifically Vd2 neg gdT cells that are reactive against CMV-infected cells. [13] [14] [15] [16] [17] Furthermore, expansion of Vd2 neg T cells upon CMV infection was shown to correlate with clearance of the virus. 18 In addition to the anti-CMV response, numerous studies have implicated gdT cells in tumor host defense: gdT cells have been found to infiltrate tumors of diverse origin in vivo, [19] [20] [21] and both Vd2 neg and Vd2 pos subsets have been abundantly shown to be cytotoxic to cancer cells in vitro. 10, [22] [23] [24] Taken together, these reports have strongly established the importance of Vd2 neg gdT cells in the immune response against CMV and in tumor surveillance. In the present study, we therefore evaluated the potential anti-leukemia capacity of gdT cells that expand upon CMV reactivation in a population of patients with hematological malignancies receiving allo-SCT from either conventional or cordblood donors. We show that in this cohort CMV reactivation after allo-SCT associates with in vivo expansions of CMV-reactive Vd2 neg gdT cells. These CMV-induced gdT cells are capable of cross-recognizing hematological cancers, and thus may explain the favorable effect of CMV reactivation on risk of leukemic relapse. In addition, such cells can serve as tools either from third-party donors to tackle CMV infection and leukemia or by taking advantage of here-identified receptors to redirect T cells against leukemia. 25,26 After allo-SCT, patients were weekly monitored for 3 months for CMV reactivation by real-time automated CMV-DNA PCR using a TaqMan probe. For patients with conventional stem cell donors, peripheral blood mononuclear cells of these time points were isolated and stored in liquid nitrogen until phenotypic analysis or expansion. Blood samples of cordblood patients were collected 50-100 days after transplantation. Absolute counts of CD3 þ , gdTCR þ and Vd2 þ T cells were determined using TRUcount tubes (BD, San Jose, CA, USA), according to the manufacturer's protocol. peripheral blood mononuclear cells were stained for gdTCR, Vd2, CD3, CD4, CD8a, CD16, CD25, CD27, CD45RO, CD56, CD80 and HLA-DR. The cohort of newborns with CMV infection has been described recently. 17 Expansion and isolation of gdT-cell lines. gdT cells were isolated and expanded using a previously described rapid expansion protocol (REP) 27 (see Supplementary Methods).
MATERIALS AND METHODS
Functional T-cell and dendritic cell (DC) maturation assays. Interferon-g (IFNg) enzyme-linked immunosorbent spot, 51 Chromium-release and DC-maturation assays were performed as previously described 28, 29 (see Supplementary Methods).
Cloning of gdTCRs and retroviral transduction of T cells. gdTCRs were isolated and sequenced as described in Supplementary Methods. Clone TCRs, Vg9Vd2-TCR clone G115 30 and a HLA-A*0201-restricted WT1 126-134 -specific abTCR 31 were transduced into abT cells as described 27, 29, 32 (see Supplementary Methods).
Statistical analyses. Differences were analyzed using indicated statistical tests in GraphPad Prism 5.0 for Windows (GraphPad Software Inc., La Jolla, CA, USA).
RESULTS
CMV reactivation after allo-SCT associates with expansion of Vd2 neg gdT cells in both CMV-positive and CMV-negative stem cell donors To test whether an increase in Vd2 neg gdT cells is observed during CMV reactivation after allo-SCT, blood samples of 26 patients with umbilical cordblood (n ¼ 10) and adult stem cell donors (n ¼ 16, Supplementary Figure 1A) , suggesting expansion of effector cells in these patients. Also all patients with cordblood grafts, thus CMV-naive donors, that developed a CMV reactivation (n ¼ 6) had significantly increased numbers of circulating gdT cells when compared with time-matched non-CMV-reactivating patients (n ¼ 4; Figure 1a , right panel), although because of logistic challenges, no time-course evaluation was possible in this cohort. In both patient populations, the increase in gdT cells was due to an increase in the Vd2 neg subset (Figure 1b) , whereas Vd2 pos gdT cells did not significantly differ between CMV-reactivating and nonreactivating patients (adult grafts: median 2.17 versus 2.39 cells/ml, P ¼ 0.37; cordblood grafts: median 4.38 versus 0.81, P ¼ 0.38). No differences were observed in total CD3 þ T-cell numbers between CMV-reactivating and nonreactivating patients (adult grafts: median 437 versus 355 cells/ml, P ¼ 0.80; cordblood grafts: median 58 versus 97 cells/ml, P ¼ 0.38). To assess whether the increase in Vd2 neg gdT cells during CMV reactivation was mainly driven by gdT cells expressing a public Vg8 Vd1 TCR, which has been reported to have a substantial role in congenitally infected newborns, 17 clonality of increased cell fractions was analyzed by spectratyping. However, when analyzing clonality of Vd1, Vd2 and Vd3 gdT cells, no such enrichment was observed in selected patients (Supplementary Figure 2) . Interestingly, the increase in gdT cells in CMV-reactivating patients preceded the increase of abT cells, as a significant difference in abT cells between CMV-reactivating and nonreactivating patients was not observed until 3 months after allo-SCT (Supplementary Figure 1B) .
Together, these data confirm in a rather small but apparently representative cohort that CMV reactivation after transplantation of CMV-seropositive stem cell grafts associates with a significant increase of donor Vd2 neg gdT cells. Notably, Vd2 neg gdT cells were also elicited during CMV reactivation when CMV-naive cordblood grafts were used.
Patient-derived Vd2
neg gdT cells specifically recognize CMV-infected and transformed cells ex vivo To functionally evaluate whether Vd2 neg gdT cells that expanded in vivo upon CMV reactivation could indeed contribute to an anti-CMV immune response, gdT cells were isolated from CMV-reactivating patients and analyzed ex vivo. Patient-derived bulk, Vd2 neg and Vd2 pos gdT-cell subsets were coincubated with CMV-infected fibroblasts, and gdT-cell activation was measured by IFNg enzyme-linked immunosorbent spot. gdT cells isolated from patients with conventional stem cell grafts secreted significantly higher levels of IFNg upon contact with CMV-infected cells when compared with uninfected controls (Figure 2a ). In line with previous studies, 13, 14 CMV reactivity of patient-derived gdT cells was mediated exclusively by Vd2 neg gdT cells, but not Vd2 pos gdT cells (Figure 2a ). Importantly, gdT cells isolated from cordblood patients produced IFNg in response to and were able to specifically lyse CMV-infected cells (Figure 2b ).
Previously it has been reported that gdT cells that expand upon CMV reactivation are able to cross-recognize solid cancer cells, 33, 34 however, cross-reactivity with leukemic cells has not been reported. Therefore, patient-derived Vd2 neg and Vd2 pos gdT cells CMV-and leukemia-reactive gdT cells after allo-SCT W Scheper et al were coincubated with a variety of hematological cancer cell lines and primary AML blasts. Indeed, CMV-reactive Vd2 neg gdT cells were able to specifically recognize lymphoma (Daudi), leukemia (BV173, K562 and KCL22) and myeloma (U266) cell lines, and most importantly primary AML blasts ( Figure 2c ). In contrast, Vd2 pos gdT cells from selected patients responded to hematological cell lines but not to primary AML samples, although reactivity could be induced after treating AML cells with the bisphosphonate pamidronate, a compound that induces the accumulation of Vd2 pos gdT-cell-activating phosphoantigens in treated cells 29 (data not shown).
In summary, CMV reactivation after allo-SCT associates with an increase in multipotent Vd2 neg gdT-cell populations from both CMV-positive and naive stem cell donors that are able to recognize both CMV-infected cells and hematological tumor cells.
CMV-reactive Vd2
neg gdT-cell clones cross-recognize leukemic cells, including primary AML blasts To investigate whether cross-reactivity of Vd2 neg gdT cells to leukemic blasts and CMV-infected fibroblasts is restricted to different clonal populations, Vd2 neg gdT cells were cloned by limiting dilution. All generated clones carried Vd1 pos gdTCRs and expressed the NK receptor NKG2D (Figure 3a and Supplementary Figure 3 ). Two clones (B11 and E1) heterogeneously expressed CD8aa. CMV reactivity of generated clones was subsequently analyzed by coincubation with either CMV-infected or uninfected fibroblasts. Two Vd1 pos gdT-cell clones (B11 and E1) responded to CMV-infected fibroblasts by increased IFNg production, whereas two other clones (D3 and E2) did not ( Figure 3b ). None of the clones produced tumor necrosis factor-a (TNFa) in response to CMV-infected cells (data not shown). Next, CMV-reactive Vd1 pos gdT-cell clones B11 and E1 were coincubated with the hematological tumor cell lines U266, T2 (T-and B-lymphoblastoid cell line), Epstein-Barr virus-transformed lymphoblastoid cell line or primary AML blasts. Both CMV-reactive clones displayed a potent IFNg response against all (clone B11) or most (clone E1) tested tumor cell lines, as well as primary AML samples (Figure 3c ), but not healthy fibroblasts. However, leukemia reactivity was not a feature of all isolated clones, as clones D3 and E2 did not produce IFNg or TNFa in response to leukemic cell lines or blasts (data not shown). Together, these data suggest that here-isolated CMV-reactive clones are able to cross-recognize hematological tumor cells.
The interaction of Vd2 neg gdT cells with DCs is clonally segregated from CMV and leukemia reactivity and is mediated by individual gdTCRs Because isolated clones D3 and E2 did not show a cytokine response against CMV-infected fibroblasts nor leukemic cells (data not shown), we hypothesized that such clones elicited after CMV neg gdT cells were measured in the second and third month after allo-SCT, in patients with cordblood grafts at the same time point as in a. In box plots, the line at the middle is the median, the box extends from the 25th-75th percentile, and the whiskers extend down to the lowest value and up to the highest. Mann-Whitney U-test was used to assess differences between CMV-positive and CMV-negative patients, and significant differences are indicated (*Po0.05).
infection are involved in maturation of DCs, 35 and thereby may aid in mounting adaptive immune responses. Therefore, monocytederived immature DCs were cultured alone or in the presence of Vd1 pos gdT-cell clones, and expression of the maturation markers CD80 and CD86 on DCs was measured after 48 h. Selectively, in the presence of Vd1 gdT-cell clones D3 and E2, but not CMV-and leukemia-cross-reactive clones B11 and E1, a substantial and significant increase in CD80/CD86 þ DCs was observed compared with immature DCs alone (Figure 3d ), resembling the phenotype of DCs matured by the classical maturation cocktail (prostaglandin E2, IL-1b, IL-6 and TNFa). 36 However, no detectable production of IL12p70 was induced by Vd1 gdT-cell clones (data not shown).
Importantly, induction of this characteristic mature phenotype of DCs by clones D3 and E2 was observed in the absence of CMV-infected cells or CMV virions in cocultures, indicating that maturation of DCs by Vd2 neg gdT-cell clones is independent of CMV-antigen.
To test whether induction of maturation markers on DCs by Vd1 pos T-cell clones D3 and E2 is mediated by their gdTCRs, Vg (Vg4, Vg8 and Vg9) and Vd1 chains of here-generated clones were sequenced (Supplementary Table 3 ) and retrovirally transduced into abT cells. In agreement with our previous data on Vg9Vd2 TCRs, 29 all clone-derived d1-TCRs were efficiently expressed in both CD4 þ and CD8 þ abT cells and -test (a, b) or one-way analysis of variance (ANOVA) (c) was used to assess differences between gdT-cell responses (*Po0.05; **Po0.01; and ***Po0.001).
downregulated endogenous abTCRs (Supplementary Figure 4) . The involvement of individual d1-TCRs in the induction of the mature-like phenotype of DCs was subsequently analyzed by incubating transduced T cells with immature monocyte-derived DCs. Selectively d1-TCRs that were isolated from clones E2 and D3 but neither d1-TCRs E1 and B11 nor mock-transduced cells induced a marked (B3.5-to 9-fold) upregulation of CD80/CD86 on DCs (Figure 3e ) and increased TNFa secretion in culture Figure 5A) . In addition, a higher mean expression of CD40, CD83 and HLA-DR was detected on DCs after coincubation with E2-TCR-and D3-TCR-transduced T cells, but not T cells expressing d1-TCRs E1 and B11. This phenotype depended on both CD1c, a lipid-presenting molecule previously reported to be involved in Vd2 neg gdT-cell-mediated DC maturation, 35 and TNFa (Supplementary Figure 5B) . As was observed in experiments with original clones, DCs did not produce detectable levels of IL12p70 (data not shown). Taken together, these data show that distinct clonal populations within the expanded Vd2 neg gdT-cell subset are responsible for CMV and leukemia reactivity and for interacting with DCs, and that the Vd2 neg gdT cell-DC interaction involves defined d1-TCRs.
Cancer reactivity, but not CMV reactivity, is mediated by distinct gdTCRs To formally confirm that individual gdTCRs of Vd1 clones B11 and E1 mediate CMV reactivity, as reported after in primo utero CMV infection, 17 abT cells transduced with clone-derived d1-TCRs and the previously reported CMV-reactive Vg8 Vd1 TCR 17 were incubated with CMV-infected or uninfected fibroblasts. Surprisingly, only T cells expressing the public CMV-reactive Vg8 Vd1 TCR but neither here-cloned CMV-reactive nor nonreactive d1-TCRs produced IFNg after contact with CMV-infected cells (Figure 4a and data not shown), suggesting that CMV recognition by original clones B11 and E1 must rely on alternative surface receptors.
To test the mechanism involved in tumor recognition, clones B11 and E1 were tested for expression of NKp30, a receptor recently reported to be involved in antitumor reactivity by Vd1 pos gdT cells. 22 However, here-isolated clones did not express NKp30 (Supplementary Figure 3) . Thus, an alternative mechanism must mediate tumor reactivity and could include the individual gdTCRs. Therefore, d1-TCR-and mock-transduced abT cells were cocultured with hematological cancer cell lines or primary AML blasts, and T-cell activation was determined by IFNg enzyme-linked immunosorbent spot. Selectively, T cells transduced with d1-TCRs 
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of CMV-and cancer-reactive clones B11 and E1, but not mock-transduced T cells, were able to recognize both hematological cancer cell lines and primary AML cells, whereas healthy T cells were not recognized (Figure 4b) . Importantly, cancer reactivity of both d1-TCRs could be extended to solid cancers, because pharyngeal (Fadu) and breast cancer (MDA-MB231) cell lines also activated gdTCR-transduced T cells (Figure 4b ). T cells transduced with d1-TCRs D3 or E2 produced neither IFNg nor TNFa against tested cancer cells (data not shown). Thus, cancer reactivity of selected Vd1 pos gdT-cell clones is mediated by their respective d1-TCRs, and this reactivity can be transferred to previously nonreactive abT cells.
CD8aa functions as critical coreceptor for selected tumor-reactive d1-TCRs d1-TCRs isolated from clones B11 and E1 can be suitable tools to redirect abT cells against leukemias as reported for Vg9Vd2-TCR clone G115, which reprograms both CD4 þ helper and CD8 þ cytotoxic abT cells against a broad panel of tumor cells. 29 Thus, we questioned whether also here-isolated tumor-reactive Vd1 pos gdTCRs are able to redirect both subsets of abT-cells, CD4 þ and CD8 þ , against cancer cells. CD4 þ and CD8 þ T cells expressing tumor-reactive d1-TCRs B11 or E1 were therefore separated and incubated with T2 or Daudi target cell lines. CD4 þ and CD8 þ abT cells transduced with d1-TCR E1 produced similar levels of IFNg in response to tumor target cells (Figure 5a ). In sharp contrast, d1-TCR B11 was able to reprogram CD8 þ but not CD4 þ T cells, even though the introduced B11 TCR was expressed at slightly higher levels in CD4 þ than in CD8 þ T cells (Supplementary Figure 4B) , as reported previously. 29, 37 This suggested that for full T-cell activation, this gdTCR requires a molecule present on CD8 þ but not CD4 þ abT cells, such as NKG2D or CD8. To address this, CD8 þ T cells transduced with the B11 d1-TCR were preincubated with blocking antibodies against CD8a, CD8b or NKG2D and subsequently coincubated with Daudi or T2 target cells. Blocking of NKG2D, which is expressed on most CD8 þ but not CD4 þ abT cells and can amplify ab-and gdT-cell responses, 38, 39 had only an effect on target cell recognition when T cells were transduced with a g9d2TCR as reported 29 (data not shown). Strikingly, blocking CD8a but not CD8b resulted in a marked decrease in IFNg secretion when compared with T cells pretreated with control antibody (Figure 5b ). Blocking capacity of CD8b antibody was confirmed by inhibiting MHC class I-restricted abT cells. CD8a blocking on CD4 þ T cells expressing the B11 or E1 d1-TCRs served as additional negative controls and did not influence T-cell responses. Thus, the CD8a, but not CD8b, domain is important in the ligand interaction of the B11 d1-TCR. These data indicate that depending on the particular gdTCR, tumor reactivity is mediated by CD8a-dependent and -independent mechanisms, suggesting, for example, different affinities of herecloned TCRs to their ligands.
The original clone B11 expressed the CD8aa homodimer but not the CD8ab heterodimer (Supplementary Figure 3) . To test whether CD8aa was also involved in activation of the original B11 gdT-cell clone, clones B11 (CD8 þ ) and E1 (CD8 low ) were cocultured with T2 target cells in the presence of CD8a-or CD8b-blocking antibodies. Similar to the effect on T cells transduced with the B11 d1-TCR, blocking of CD8a significantly inhibited IFNg production by the original clone (Figure 5c ). However, the effect of CD8a blocking was less pronounced on the original clone compared with B11-transduced abT cells, most likely due to lower expression of CD8aa on the parental clone when compared with CD8ab expression on transduced T cells (data not shown). Again, blocking of CD8b did not affect IFNg secretion, as expected based on the CD8aa-positive phenotype of clone B11. As was observed in E1-transduced T cells, CD8a/b blocking did not affect activation of clone E1 (Figure 5c ). To corroborate these observations, additional CD8aa-positive Vd1 T-cell clones were generated from a different donor, and the effect of CD8a blocking on activation of clones was analyzed. Of nine CD8aa þ clones tested, blocking CD8a, but not CD8b, inhibited activation of one clone that reacted to the colorectal cancer cell line SW480 (clone FE11), as measured by reduced IFNg secretion (Figure 5d ). CD8a blocking had no effect on activation of the parental polyclonal Vd2 neg CD8 þ gdTcell line of this donor nor of two other donors (data not shown), suggesting that CD8 dependence of defined gdT-cell clones is not a general phenomenon, yet observed in a substantial fraction (2 out of 10) of isolated clones.
CD8aa was in the majority of isolated clones not functionally involved in tumor reactivity, questioning whether CD8aa rather has a general role in CMV reactivity. In order to assess whether an increase in CD8aa expression on gdT cells might be linked to CMV infection in vivo, the cohort of conventional stem cell donors was analyzed for CD8 expression by flow cytometry. Strikingly, CMV-reactivating patients had significantly more circulating CD8 þ gdT cells compared with nonreactivating patients (Figure 6a ). This observation was confirmed in a complementary cohort of congenitally CMV-infected newborns (Figure 6b) Figure 6) . Microarray gene-expression profiling revealed highly upregulated expression of CD8a but not CD8b upon CMV infection (Figure 6c ), and flow cytometry on blood samples of infected individuals indeed showed that CMVassociated expression of CD8 on gdT cells is preferentially of the aa homodimer (Figure 6d ). Of note, CD8 þ abT cells sorted from the same CMV-infected newborns did not show increased expression of CD8a (Figure 6d ). To test whether CD8aa has a functional role in CMV reactivity by Vd2 neg gdT cells, clones B11 and E1 were coincubated with CMV-infected or uninfected fibroblasts in the presence of CD8a-blocking antibody. However, blocking CD8aa inhibited not only the specific recognition of CMV-infected cells but also the occasionally observed background reactivity of clone B11, but not clone E1, against freshly plated fibroblasts (data not shown), suggesting that CD8aa may interact rather with a general stress antigen than an antigen specific for CMV infection.
In summary, these data show that CD8aa expressed on human Vd2 neg gdT cells associates with CMV infection in vivo and is able to function as a critical costimulator on selected clones as well as on gdTCR-reprogrammed abT cells when coincubated with tumor cells.
DISCUSSION
The contribution of Vd2 neg gdT cells to controlling CMV infection has received considerable attention in recent years, and it is now well established that these unconventional T cells have important roles in the immune response to CMV infection. [13] [14] [15] 17, 34 Combined with their widely reported reactivity towards a variety of (mainly solid) tumors, 19, 21, 23 this has made Vd2 neg gdT cells a promising cell population for immunotherapeutic application. In the present study, we demonstrate that Vd2 neg gdT cells that expand upon CMV reactivation after allo-SCT are capable of responding to both CMV-infected and leukemic cells. In addition, by demonstrating that tumor reactivity of Vd2 neg gdT cells can be transferred by gdTCR gene transfer, and by identifying a novel role for CD8aa in the antigen restriction of gdTCRs, we provide a solid basis for the therapeutic exploration of Vd2 neg gdT cells and their gdTCRs.
Our observation that the occurrence of a single event (that is, CMV infection) is able to induce expansion of gdT-cell subsets with anti-CMV and anti-leukemia reactivity, including reactivity against primary leukemic blasts, provides an alternative explanation for recent unexpected findings of a reduced relapse rate in patients with CMV reactivation after allo-SCT. 5, 6 Furthermore, it is in line with a report in kidney transplant patients demonstrating that expansion of Vd2 neg gdT cells following CMV infection associated with a reduced risk of developing solid cancer post transplantation. 33 gdT cells isolated from these patients reacted against both CMV-infected cells and epithelial tumor cells in vitro. Thus, although CMV reactivation after allo-SCT is still associated with substantial nonrelapse-related mortality (for example, graftversus-host disease, colitis and secondary infections), reactivation of the virus reduces the risk of mortality because of relapse of leukemia, and we show that one possible link is a CMV-induced expansion of leukemia-reactive gdT cells. This hypothesis is further substantiated by clinical data demonstrating that increased numbers of gdT cells after allo-SCT are associated with improved disease-free survival, without higher incidence of graft-versus-host disease. 40 Mechanistically, little is known about the requirements for gdT-cell activation, and the identity of the molecules on CMVinfected and leukemic cells that are recognized by here-generated gdT-cell clones so far remain elusive. Dual reactivity of Vd2 neg gdT-cell clones to CMV and solid cancer cells has been reported and has led to the hypothesis that gdTCRs of dual-reactive cells recognize shared antigens on CMV-infected and transformed cells. 34, 41 However, our gdTCR gene-transfer experiments show that cancer reactivity, but not CMV reactivity, is mediated by d1-TCRs isolated in this study, indicating that alternative immune receptors may be responsible for CMV reactivity of the original clones or that the gdTCR is involved but depends on additional molecules not expressed on abT cells. In line with this, it was recently reported that the gdTCR isolated from a CMV-reactive Vg4Vd5 clone requires costimulation by CD11a-CD18 (LFA-1). 41 However, here-isolated CMV-reactive clones E1 and B11, as well as abT cells transduced with their respective gdTCRs, expressed high levels of CD11a (see Supplementary Figure 7 ), suggesting that other mechanisms must be involved. Alternatively, it was recently shown that Vd2 neg gdT cells could be stimulated by IgG-opsonized CMV virions via the IgG receptor CD16 (FcgRIIIa), independent of gdTCR engagement. 42 However, here-isolated CMV-reactive clones did not express CD16 (see Supplementary Figure 3) .
We report here for the first time that in human gdT cells, CD8aa functions as restriction element for target recognition by distinct d1-TCRs. Although long described to be expressed on gdT cells, 11, 12 the function of CD8aa on these cells has so far remained unknown. In our experiments, blocking CD8a resulted in a marked and significant inhibition of tumor recognition by different clones and distinct d1-TCRs, which was not observed when tested on the bulk population. These data put CD8aa into the field of coreceptors for d1-TCRs for a defined subset of tumorreactive gdT cells. Moreover, we report that CMV infection associates with an increase in CD8aa-expressing gdT cells in both allo-SCT patients and congenitally infected newborns, suggesting a link between CD8aa and the immune response against CMV in vivo. However, the functional involvement of CD8aa in gdT-cell-mediated CMV reactivity remains to be further defined. Within the abT-cell compartment, CD8aa-positive T cells are enriched in mucosal tissues, such as intestine, and these cells are described to display a characteristic innate-like phenotype. 43 However, on these cells, CD8aa does not function as a classical MHC class I-binding abTCR coreceptor as CD8ab does, but more likely serves as suppressor of abTCR-mediated T-cell activation. 44 CMV-and leukemia-reactive gdT cells after allo-SCT W Scheper et al A subset of NK cells also expresses CD8aa, and these cells posses greater killing capacity than CD8aa-negative NK cells. 45 This effect was attributed to enhanced resistance to apoptosis that was specifically mediated through CD8aa signaling. 46 Superior cytotoxicity of CD8aa-expressing NK cells has been associated with clinical remission of leukemia patients, 47, 48 indicating that CD8aa on innate immune cells may be relevant to clinical outcome after allo-SCT. Finally, CD8aa on murine innate-like intestinal abT-cells was shown to enhance abTCR-mediated T-cell activation by binding the nonclassical MHC-I molecule thymus Figure 6 . CMV reactivation after allo-SCT and congenital CMV infection associate with increased expression of CD8 on gdT cells. (a) The percentage of CD8 þ gdT cells of patients with conventional stem cell donors was measured in the second and third month after allo-SCT by flow cytometry. (b) Cord blood from fetuses congenitally infected (n ¼ 11) or not infected (n ¼ 16) was collected at term delivery, and the percentage of gdT cells expressing CD8 was analyzed by flow cytometry. (c) Gene-expression analysis of gdT cells derived from three CMV-infected newborns versus gdT cells derived from three CMV-uninfected newborns. MA plot of differentially expressed genes in gdT cells upon CMV infection. M (log2 of fold change) reflects the differential expression of a gene. Positive and negative values indicate genes which are up-and downregulated, respectively, upon CMV infection. A (mean expression) reflects the overall expression level of a gene. Note that a similar figure, with indication of other genes, has been published before. 17 The highly upregulated expression of CD8a RNA is indicated. The downregulation of CD28 RNA is indicated as well for comparison. (d) The majority of CD8 on gdT cells of congenitally infected newborns is composed of the CD8aa homodimer. Percentages of CD8 þ gdT cells and CD8 þ abT cells expressing the CD8a þ CD8b À phenotype were determined by flow cytometry in cordblood samples from eight congenitally infected newborns (left panel). Representative flow cytometry plots (right panel) illustrate the staining patterns of CD8a and CD8b on abT and gdT cells. Mann-Whitney U-test (a, b) and Student's t-test (d) were used and significant differences are indicated (*Po0.05 and ***Po0.001).
CMV-and leukemia-reactive gdT cells after allo-SCT W Scheper et al leukemia. 49 Thus, the expression of CD8aa on innate(-like) immune cells may indicate a universal role for CD8aa as regulatory receptor in innate immune responses.
To tackle CMV infections in immunocompromised patients, several clinical trials have focused on the adoptive transfer of CMV-reactive abT cells. 50, 51 However, major obstacles are presented by the MHC-restricted antigen recognition of abT cells and the challenge to generate sufficient numbers of CMV-reactive abT cells within the time constraints of severe infection. 52 Our data suggest that Vd2 neg gdT cells are an interesting alternative source of CMV-reactive T cells for such patients, as we observe that in vivo generated Vd2 neg gdT cells react against not only CMV-infected cells but also leukemic cells in vitro. Moreover, we demonstrate that CMV-reactive gdT cells can also be obtained from the naive umbilical cordblood repertoire, underscoring the value of this third-party stem cell source for application in allo-SCT, in particular also for patients with CMV-negative donors. In summary, we advocate the exploration of adoptive transfer of unmodified Vd2 neg gdT cells in CMV and tumor immunotherapies and the application of leukemia-reactive Vd1-TCR-engineered T cells. Clinical trials will need to be pursued in order to test efficacy and safety of the application of such strategies.
